Formosa Laboratories, Inc. is a Contract Development and Manufacturing Organization (CDMO) established in 1995 that provides API process development, impurity identification, and synthesis services. The company entered GMP API manufacturing in 2000 and offers facilities for Active Pharmaceutical Ingredients (APIs), High Potency APIs (HPAPIs), Antibody-Drug Conjugates (ADCs), and injectables. Its service portfolio includes custom synthesis, bioconjugation, injectable manufacturing, custom fermentation, and peptide synthesis, supporting clients from pilot plant to commercial scale. Formosa Laboratories manufactures generic medicines, including Eribulin Injection, which has received approval from the U.S. Food and Drug Administration and marketing approval in Europe. The company partners with Jiksak Bioengineering Inc. to develop ADC innovations for neurological diseases and collaborates with a U.S. pharmaceutical company for the supply of breast cancer chemotherapy injections. Its manufacturing processes comply with cGMP regulations and are inspected by the TFDA, FDA, EDQM, and PMDA.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage formosalab.com
Sector Healthcare IR page formosalab.com/investor
Tags
contract development and manufacturing, active pharmaceutical ingredients, high potency apis, antibody-drug conjugates, injectable manufacturing, peptide synthesis, custom fermentation, generic medicines, oncology, neurological diseases, Eribulin Injection, Jiksak Bioengineering Inc.
Press page formosalab.com/news

Metrics

Valuation  
Market cap NT$ 4.937B
Market cap (USD) $ 149.832M
P/E 12.40
PEG 4.92
P/BV 0.64
P/S 1.02
P/OCF 6.80
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 5.7%
ROI 5.7%
ROIC 8.2%
Profit margin 9.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 2.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score 56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 4.851B 4.731B 4.36B 3.766B 3.142B 3.075B 2.76B 2.688B 2.539B 3.189B 2.597B 2.496B 2.474B 2.524B 2.626B 2.506B
Net profit 441.107M 157.268M 126.243M 409.359M 1.249B 400.034M 11.631M 176.821M 238.645M 483.441M 282.392M 262.495M -69.401M 5.003M 231.067M 246.621M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 59.3 68.8 102 73.5 60.5 46.95 — — — — — — — — — —
Price performance 12m -0.14 -0.33 0.39 0.21 0.29 — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Formosa Laboratories, Inc. (ticker 4746.TW), listed in Taiwan.

ETFs Holding Formosa Laboratories, Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 12,000 $ 16.414K Nov 16, 2026
DEXC 0.00% 8,000 $ 11.101K Nov 12, 2026
DFEV 0.00% 59,000 $ 81.871K Nov 12, 2026
DFEM 0.00% 167,000 $ 231.737K Nov 12, 2026
DFAE 0.00% 115,000 $ 159.579K Nov 12, 2026
DFAX 0.00% 74,108 $ 102.836K Nov 12, 2026
AVEM 0.00% 160,000 $ 218.852K Nov 16, 2026
AVES 0.00% 22,000 $ 30.092K Nov 16, 2026
AVSE 0.00% 2,000 $ 2,735.65 Nov 16, 2026
AVXC 0.00% 6,000 $ 8,206.96 Nov 16, 2026